Emergence of dalbavancin, vancomycin, and daptomycin non-susceptible Staphylococcus aureus in a patient treated with dalbavancin: Case report and isolate characterization
alexandrossfakianakis shared this article with you from Inoreader
A patient with end-stage renal disease received 2 doses of dalbavancin for methicillin-resistant Staphylococcus aureus arteriovenous fistula infection and presented 5-weeks later with infective endocarditis secondary to vancomycin, daptomycin, and dalbavancin non-susceptible MRSA. Resistance was associated with walK and scrA mutations, reduced long-chain lipid content, and reduced membrane fluidity.
No comments:
Post a Comment